Have questions on Uptravi (Selexipag)?
QuickRx can help.

Uptravi (selexipag) copay assistance refers to the savings programs, patient assistance programs, and foundation grants that help eligible patients lower what they pay out of pocket for their prescription. These programs are funded and administered by the drug manufacturer or by independent nonprofit foundations, and each sets its own eligibility rules.

The programs are free to apply for, but they can be difficult to find, enroll in, and keep active. QuickRx Specialty Pharmacy provides free enrollment support: our patient navigators identify which programs you may qualify for, complete the applications, and manage renewals so your coverage does not lapse.

QuickRx Specialty Pharmacy does not issue, sponsor, or administer manufacturer copay cards or patient assistance programs. Eligibility and terms are set by the program sponsor and are subject to change. QuickRx cannot guarantee enrollment or any specific savings amount.

No. Manufacturer copay cards cannot be used by patients enrolled in Medicare, Medicaid, TRICARE, or other federal or state healthcare programs. This restriction comes from federal law and applies to every manufacturer copay card, not just Uptravi.

Other options may still be available. Patients with government coverage may be able to access independent charitable foundation grants or manufacturer patient assistance programs, depending on diagnosis, income, and plan. QuickRx reviews which options apply and handles the paperwork at no cost. Call (917) 830-2525.

Eligibility for foundation grants and patient assistance programs is determined by the sponsoring organization. Funding availability, diagnosis requirements, and income limits vary by program and change without notice.

No. There is no generic selexipag available in the United States at this time. Uptravi is currently available only as a brand-name product from Actelion Pharmaceuticals US Inc.

If that changes, generic selexipag would be required to meet the same FDA standards for active ingredient, strength, dosage form, and route of administration as the brand.

Generic availability status per Lexidrug (UpToDate Lexidrug), last updated July 20, 2026. Availability is subject to change; contact QuickRx for current information.

Published benchmark pricing for Uptravi is approximately $484.54 per tablet for the 400 mcg through 1,600 mcg strengths, and approximately $311.57 per tablet for the 200 mcg strength. The Uptravi Titration therapy pack is listed at approximately $218.10 per unit, and the 1,800 mcg intravenous vial at approximately $483.62 each.

These are Average Wholesale Price (AWP) benchmark figures, not what a patient pays. Your actual out-of-pocket cost depends on your insurance plan, formulary placement, deductible, and any assistance programs you qualify for. Call (917) 830-2525 and we will review your coverage.

Pricing per Lexidrug (UpToDate Lexidrug), Medi-Span AWP data, accessed July 2026. AWP is a reference benchmark provided for comparison purposes only and should not be used to set, adjudicate, or predict any individual patient price. QuickRx Specialty Pharmacy does not set drug prices and cannot guarantee any specific cost or savings amount.

No. QuickRx provides copay assistance enrollment support free of charge. There is no fee to the patient for this service.

Our patient navigators review your insurance coverage, identify programs you may qualify for, complete applications, coordinate with your prescriber for required documentation, and manage renewals and insurance changes.

Uptravi (selexipag) is a prescription medication used to treat pulmonary arterial hypertension (PAH), also known as WHO Group I pulmonary hypertension. It belongs to a class of medications called prostacyclin IP receptor agonists.

• Drug class: Prostacyclin; prostacyclin IP receptor agonist; vasodilator
• FDA approved: December 21, 2015
• Manufacturer: Actelion Pharmaceuticals US Inc
• Available forms: Oral tablets and intravenous solution

Uptravi is indicated in adult and pediatric patients 2 years of age and older to delay disease progression and reduce the risk of hospitalization for PAH.

Selexipag is a selective prostacyclin IP receptor agonist. Prostacyclin is produced in the endothelial cells and induces vasodilation, and it also inhibits platelet aggregation.

Patients with pulmonary arterial hypertension appear to have a dysregulation in the prostacyclin metabolic pathways. Selexipag is hydrolyzed to an active metabolite, ACT-333679, which is a major contributor to the drug’s activity.

The usual starting dose is 200 mcg taken orally twice daily, increased by 200 mcg twice daily at approximately weekly intervals until an adequate therapeutic response or the highest tolerated dose is reached. The maximum dose is 1,600 mcg twice daily.

If a dose is not tolerated, the dose is reduced to the previously tolerated dose. Uptravi should be managed by a pulmonary arterial hypertension specialist and may be useful as a third agent in patients already receiving combination therapy.

Your prescriber determines your dose. Always take Uptravi exactly as prescribed.

Titration means gradually adjusting the dose over time to find the right amount for your body. Uptravi is started at a low dose and increased in 200 mcg steps, usually at weekly intervals, until you reach either an adequate response or your highest tolerated dose.

Side effects are often most noticeable during titration. If a dose is not tolerated, your prescriber may reduce you to the previously tolerated dose.

Uptravi tablets may be taken with or without food, and tolerability may be improved when taken with food. Swallow tablets whole; do not split or crush them.

For patients who cannot swallow tablets whole (100 mcg and 150 mcg tablets only)

• The tablets may be dispersed in apple or orange juice. Do not use water or milk.
• Add at least 1 mL of juice per tablet, wait 5 minutes, then stir until dispersed. Administer immediately and do not store for later use.
• Alternatively, cover the tablets with a soft food such as applesauce, mashed banana, or yogurt and administer immediately.

If a dose is missed, take it as soon as possible unless your next dose is within the next 6 hours. If your next scheduled dose falls within 6 hours, skip the missed dose.

If 3 or more days of treatment are missed, treatment is restarted at a lower dose and then retitrated. Contact your prescriber or one of our pharmacists before restarting.

The most commonly reported side effect is headache, which occurred in 65% of adults in clinical studies. Side effects tend to be most noticeable during titration.

Reported in more than 10% of patients

• Headache (65%)
• Diarrhea (42%)
• Nausea (33%)
• Jaw pain (26%)
• Vomiting (adults 18%; children and adolescents 39%)
• Limb pain (17%)
• Myalgia, or muscle pain (16%)
• Abdominal pain (children and adolescents 15%)
• Flushing (12%)
• Skin rash (11%)
• Arthralgia, or joint pain (11%)

Reported in 1% to 10% of patients

• Anemia (8%)
• Decreased appetite (6%)
• Hyperthyroidism (1%)

Patients receiving the intravenous formulation may experience infusion-site reactions including redness, pain, or swelling at the injection site. Symptomatic hypotension has been reported after marketing.

This is not a comprehensive list. Talk to your doctor about any side effects you experience.

Contact your doctor or get medical help right away if you develop breathing problems that are new or worse. Signs and symptoms that may indicate a serious problem include:

• Trouble breathing that is new or worse
• Wheezing or coughing
• Feeling very tired or weak
• Signs of an allergic reaction: rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat

Pulmonary edema

If signs or symptoms of pulmonary edema occur, your provider will consider the possibility of associated pulmonary veno-occlusive disease (PVOD). If PVOD is confirmed, treatment is discontinued.

Uptravi is contraindicated in patients with hypersensitivity to selexipag or any component of the formulation, and in patients taking strong CYP2C8 inhibitors such as gemfibrozil.

Use with caution

• Moderate liver impairment: Dosage modification is recommended
• Severe liver impairment: Avoid use; this has not been studied

Pregnancy and breastfeeding

Human pregnancy data for selexipag is limited to case reports and is insufficient to identify drug-associated risks. Separately, pregnancy in patients with pulmonary arterial hypertension is associated with an increased risk of maternal mortality and morbidity, and patients with PAH are strongly advised to avoid pregnancy.

It is not known whether selexipag is present in human milk. Because of the potential for serious adverse reactions in a breastfed infant, the manufacturer recommends deciding whether to discontinue breastfeeding or discontinue the drug, weighing the importance of treatment to the mother.

Significant drug interactions exist with Uptravi, and some require dose adjustment or avoidance. Tell your prescriber and pharmacist about every medication and supplement you take.

• Strong CYP2C8 inhibitors: Avoid. These may increase selexipag concentrations and active metabolite exposure.
• Moderate CYP2C8 inhibitors: The selexipag dose is reduced to once daily while taking them, then returned to twice daily after stopping.
• Rifampin: May decrease active metabolite exposure. The selexipag dose may be increased up to twofold, with monitoring for reduced effectiveness.
• Cannabidiol: May increase serum concentrations of CYP2C8 substrates. Monitor.
• Lumacaftor and ivacaftor: May either decrease or increase serum concentrations of CYP2C8 substrates. Monitor.

This is not a complete list. Your healthcare provider should review all of your medications before you start Uptravi.

Liver function tests are monitored during Uptravi treatment. Your care team will also monitor for signs of pulmonary edema and for improvements in pulmonary function, exercise tolerance, and quality of life.

Report any signs or symptoms of pulmonary edema or respiratory distress to your provider promptly. Your prescriber will determine the monitoring schedule appropriate for your situation.

Kidney function generally does not require a dosage adjustment, but liver impairment does.

Kidney function

For an eGFR of 15 mL/minute or greater, no dosage adjustment is necessary. Below 15 mL/minute, and for patients on intermittent hemodialysis, the manufacturer provides no dosage adjustment because it has not been studied, though adjustment is considered unlikely to be needed since urinary excretion is limited.

Liver function

• Mild impairment (Child-Turcotte-Pugh class A): No dosage adjustment necessary
• Moderate impairment (class B): Initial dose 200 mcg once daily, increased by 200 mcg once daily at weekly intervals as tolerated, up to a maximum of 1,600 mcg once daily
• Severe impairment (class C): Avoid use

Store Uptravi tablets at 20°C to 25°C (68°F to 77°F). Brief excursions between 15°C and 30°C (59°F and 86°F) are permitted.

The 100 mcg and 150 mcg tablets should be stored and dispensed in their original package to protect them from moisture.

The intravenous formulation is stored differently: intact vials are kept refrigerated at 2°C to 8°C (36°F to 46°F) in the original container, and vials must be protected from light at all times. Intravenous preparation and administration are handled by trained healthcare professionals.